Last reviewed · How we verify
NCT01206101
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
Phase 2 trial testing liraglutide in Diabetes in 3 participants. Terminated before completion.
3 June 2013
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 21 March 2012 |
| Primary completion | 3 June 2013 |
| Estimated completion | 3 June 2013 |
| Sites | 16 locations across France, United Kingdom, Germany, Canada, Switzerland, United States |
Drugs / interventions tested
- liraglutide (liraglutide) — full drug profile →
- placebo
Conditions studied
- Diabetes — all drugs for Diabetes →
- Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
18 and older, any sex, with Diabetes or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected from week 0 to week 52.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Other adverse events (13 terms — click to expand)
| Reaction | System | Liraglutide | Liraglutide Placebo |
|---|---|---|---|
| Nausea | Gastrointestinal disorders | — | — |
| Gastric ulcer | Gastrointestinal disorders | — | — |
| Vomiting | Gastrointestinal disorders | — | — |
| Fatigue | General disorders | — | — |
| Pyrexia | General disorders | — | — |
| Pharyngitis | Infections and infestations | — | — |
| Computerised tomogram abnormal | Investigations | — | — |
| Decreased appetite | Metabolism and nutrition disorders | — | — |
| Hypoglycaemia | Metabolism and nutrition disorders | — | — |
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | — | — |
| Headache | Nervous system disorders | — | — |
| Depression | Psychiatric disorders | — | — |
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | — | — |
Data from ClinicalTrials.gov NCT01206101 adverse events section.
Sponsor's own description
This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who required only one (single-donor) islet cell transplant.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01206101
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of liraglutide
Trials testing the same drug.
- NCT07244003 — Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control · Phase 4 · recruiting
- NCT05965908 — Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome · Phase 3 · completed
- NCT05681299 — Effects of GH and Lirglutide on AgRP · Phase 4 · recruiting
- NCT03292185 — A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec a · Phase 1 · completed
- NCT02964247 — LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. · Phase 3 · completed
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01206101 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 30 March 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01206101.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing